Different Patterns of Risk Reducing Decisions in Affected or Unaffected BRCA Pathogenic Variant Carriers

Lee, Eun Gyeong; Kang, Hyok Jo; Lim, Myong Cheol; Park, Boyoung; Jung, Sung Eun; Lee, Seeyoun; Han, Kang; Park, Soo‐Jin; Park, Boram; Joo, Jungnam; Han, Jai Hong; Kong, Sun Young

doi:10.4143/crt.2018.079

Cited by 15 publications

(13 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thorough genetic counseling has impact on the decisions made associated with surgery [ 108 ]. The choice of having a risk-reducing procedure, either PBSO or RRM, differs between affected and unaffected women with BRCA mutation, the latter more often choose surveillance [ 109 ].…”

Section: Patients Diagnosed With Breast Cancer Are Not Always Aware Of Having a Brca Mutationmentioning

confidence: 99%

Management of patients with BRCA mutation from the point of view of a breast surgeon

Riis

2021

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

Germ-line mutation in BRCA (BReast CAncer gene) 1 or BRCA2 are found in 3–4% of all women with breast cancer. These patients have a significant increased risk of breast and ovarian cancer. They are often younger when diagnosed with the mutation, and the possible breast cancer they get is often aggressive with inferior outcome. There are risk reducing strategies, and the most powerful strategy is risk reducing surgery, both risk reducing bilateral mastectomy (RRM) and risk reducing bilateral salpino-oophorectomy (PBSO). This review is meant to address breast surgery in patients with germline BRCA mutation. The guidelines and techniques applied is under continuous change and it is important for the clinicians to be well informed to provide the patient with the information needed for them to make an informed decision on what risk strategy to choose.

show abstract

Section: Patients Diagnosed With Breast Cancer Are Not Always Aware Of Having a Brca Mutationmentioning

confidence: 99%

Management of patients with BRCA mutation from the point of view of a breast surgeon

Riis

2021

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

show abstract

“…After insurance reimbursement started in 2013, the rate of risk-reducing surgery was signi cantly higher (46.3% after 2013 vs. 31.6% before 2013, p < 0.001). [14] In the current study, the overall SIR for SPBC after ovarian cancer was 1.27 (95% CI, 1.09-1.46). In a study of invasive ovarian cancer, the SIR of breast cancer was 1.35 (95% CI, 0.85-2.05).…”

Section: Discussionmentioning

confidence: 49%

Characteristics of Second Primary Breast Cancer after Ovarian Cancer: A Korea Central Cancer Registry retrospective study

Lee¹,

Lim²,

Ha³

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Second primary cancer has become an important issue among cancer survivors. This study sought to determine the differences in clinicopathologic outcomes between second primary breast cancer (SPBC) after ovarian cancer and primary breast cancer (PBC) in Korea.Methods: We searched the Korea Central Cancer Registry and identified 251,244 breast cancer cases that were diagnosed between 1999 and 2017. Demographic and clinical characteristics and overall survival (OS) rates were estimated according to age, histological type, and cancer stage.Results: Among the 228,329 patients included, 228,148 were patients with PBC and 181 were had SPBC, diagnosed after ovarian cancer (OC). The most common ages at diagnosis were 50‒59 years for SPBC and 40–49 years for PBC. Patients with SPBC were significantly less likely than patients with PBC to receive adjuvant radiotherapy (14.92% vs. 21.92%, p = 0.0228) or adjuvant chemotherapy (44.75% vs. 55.69%, p = 0.0031). Based on the age-standardized rate (ASR), the incidence of SPBC after OC was 293.58 per 100,000 ovarian patients and the incidence of PBC was 39.13 per 100,000 women. The 5-year OS rates were 72.88% and 89.37% for SPBC and PBC (p < 0.0001). The OS rate in SPBC decreased significantly with advanced stage and older age.Conclusion: The incidence of breast cancer is about 1.27 times higher in ovarian cancer patients than in healthy people. The survival outcomes were worse for SPBC than for PBC and were related to older age and advanced stage. Active screening for breast cancer is necessary in ovarian cancer patients.

show abstract

“…Risk-reducing management of BRCA1/2 mutation carriers has occurred worldwide [ 13 14 ]. In carriers of the BRCA1/2 mutation, RRM lowers the risk of breast cancer by approximately 90% [ 15 16 ].…”

Section: Discussionmentioning

confidence: 99%

Trends in Risk-Reducing Mastectomy and Risk-Reducing Salpingo-Oophorectomy in Korean Carriers of the BRCA1/2 Mutation

et al. 2020

Self Cite

View full text Add to dashboard Cite

Different Patterns of Risk Reducing Decisions in Affected or Unaffected BRCA Pathogenic Variant Carriers

Abstract: RRSO was the preferred management for carriers of BRCA pathogenic variants. The most important factors in treatment choice were NHIS reimbursement and/or the severity of illness.

Cited by 15 publications

References 29 publications

Management of patients with BRCA mutation from the point of view of a breast surgeon

Management of patients with BRCA mutation from the point of view of a breast surgeon

Characteristics of Second Primary Breast Cancer after Ovarian Cancer: A Korea Central Cancer Registry retrospective study

Trends in Risk-Reducing Mastectomy and Risk-Reducing Salpingo-Oophorectomy in Korean Carriers of the BRCA1/2 Mutation

Contact Info

Product

Resources

About